[이코노믹리뷰=황진중 기자] The World Health Organization (WHO) has decided to approve the emergency use of the COVID-19 vaccine of Johnson & Johnson (J&J), a global pharmaceutical company.
According to local media on the 12th (local time), the WHO made a statement on the day and announced that it has placed the Corona 19 vaccine developed by Janssen, a subsidiary of J&J, on the list of emergency use approval.
“The data from large-scale clinical trials shared by pharmaceutical companies show that this vaccine is also effective in older people,” the WHO explained.
The previous day, the European Medicines Agency (EMA) recommended to the European Union (EU) executive committee to approve the conditional marketing use of J&J’s COVID-19 vaccine for persons 18 years of age or older. The EU Commission accepted the recommendation and approved J&J’s use of the COVID-19 vaccine. WHO made this decision based on the results of the EMA’s review.
Unlike most vaccines that require two doses, the J&J vaccine is characterized in that it can produce a preventive effect with just one dose.
WHO said, “We have reserved 500 million doses of J&J vaccines,” and explained that this is for’CoVax Facility’, a joint vaccine procurement project for developing countries.
WHO approved emergency use for Pfizer-Bioentech vaccines and AstraZeneca-Oxford University vaccines produced in Korea and India.